References

1. Jenkins C, Rentenaar RJ, Landraud L, Brisse S. Enterobacteriaceae. *Infectious Diseases*. Elsevier; 2017; 1565–1578.

2. Cohen J, Powderly WG, Opal SM. *Infectious Diseases E-Book*. Elsevier Health Sciences; 2016.

3. McClelland M, Florea L, Sanderson K, Clifton SW, Parkhill J, Churcher C, et al. Comparison of the *Escherichia coli* K-12 genome with sampled genomes of a *Klebsiella pneumoniae* and three *Salmonella enterica* serovars, Typhimurium, Typhi and Paratyphi. *Nucleic Acids Res*. 2000;28: 4974–4986.

4. Wyres KL, Holt KE. *Klebsiella pneumoniae* as a key trafficker of drug resistance genes from environmental to clinically important bacteria. *Curr Opin Microbiol*. 2018;45: 131–139.

5. Martin RM, Bachman MA. Colonization, Infection, and the Accessory Genome of *Klebsiella pneumoniae*. *Front Cell Infect Microbiol*. 2018;8: 4.

6. Kaper JB, Nataro JP, Mobley HL. Pathogenic *Escherichia coli*. *Nat Rev Microbiol*. 2004;2: 123–140.

7. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. *N Engl J Med*. 2014;370: 1198–1208.

8. Poolman JT, Wacker M. Extraintestinal Pathogenic *Escherichia coli*, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field. *Journal of Infectious Diseases*. 2016: 6–13.

9. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to public health. *Proc Natl Acad Sci U S A*. 2015;112: E3574–E3581.

10. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal *Escherichia coli*. *Nat Rev Microbiol*. 2010;8: 207–217.

11. Touchon M, Hoede C, Tenaillon O, Barbe V, Baeriswyl S, Bidet P, et al. Organised genome dynamics in the *Escherichia coli* species results in highly diverse adaptive paths. *PLoS Genet*. 2009;5: e1000344.

12. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. *Expert Rev Anti Infect Ther*. 2013;11: 297–308.

13. Llaca-Díaz JM, Mendoza-Olazarán S, Camacho-Ortiz A, Flores S, Garza-González E. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico. *Chemotherapy*. 2012;58: 475–481.

14. Organization WH, Others. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization. 2017.

15. Friedlaender C. Ueber die Schizomyceten bei der acuten fibrösen Pneumonie. *Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin*. 1882; 319–324.

16. Brisse S, Verhoef J. Phylogenetic diversity of *Klebsiella pneumoniae* and *Klebsiella oxytoca* clinical isolates revealed by randomly amplified polymorphic DNA, *gyrA* and *parC* genes sequencing and automated ribotyping. *Int J Syst Evol Microbiol*. 2001;51: 915–924.

17. Fevre C, Passet V, Weill F-X, Grimont PAD, Brisse S. Variants of the *Klebsiella pneumoniae* OKP chromosomal beta-lactamase are divided into two main groups, OKP-A and OKP-B. *Antimicrob Agents Chemother*. 2005;49: 5149–5152.

18. Brisse S, Passet V, Grimont PAD. Description of *Klebsiella quasipneumoniae* sp. nov., isolated from human infections, with two subspecies, *Klebsiella quasipneumoniae* subsp. *quasipneumoniae* subsp. nov. and *Klebsiella quasipneumoniae* subsp. *similipneumoniae* subsp. nov., and demonstration that *Klebsiella singaporensis* is a junior heterotypic synonym of *Klebsiella variicola. Int*. *J. Syst. Evol.* 2014; 64(9): 3146–3152.

19. Blin C, Passet V, Touchon M, Rocha EPC, Brisse S. Metabolic diversity of the emerging pathogenic lineages of *Klebsiella pneumoniae*. *Environ Microbiol*. 2017;19: 1881–1898.

20. Long SW, Wesley Long S, Linson SE, Saavedra MO, Cantu C, Davis JJ, et al. Whole-Genome Sequencing of a Human Clinical Isolate of the Novel Species *Klebsiella quasivariicola* sp. nov. *Genome Announc. 2017;5(42):e01057-17.*

21. Rodrigues C, Passet V, Rakotondrasoa A, Diallo TA, Criscuolo A, Brisse S. Description of *Klebsiella africanensis* sp. nov., *Klebsiella variicola* subsp. *tropicalensis* subsp. nov. and *Klebsiella variicola* subsp. *variicola* subsp. nov. *Res Microbiol*. 2019;170: 165–170.

22. Ørskov I, Ørskov F. 4 Serotyping of *Klebsiella. Methods in Microbiology.* Academic Press; 1984; 143–164.

23. Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisse S. Multilocus sequence typing of *Klebsiella pneumoniae* nosocomial isolates. *J Clin Microbiol*. 2005;43: 4178–4182.

24. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev*. 1998;11: 589–603.

25. Wyres KL, Holt KE. *Klebsiella pneumoniae* Population Genomics and Antimicrobial-Resistant Clones. *Trends Microbiol*. 2016;24: 944–956.

26. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. *Proc Natl Acad Sci U S A*. 1998;95: 3140–3145.

27. Karkey A, Thanh DP, Boinett CJ, Cain AK, Ellington M, Baker KS, et al. A high-resolution genomic analysis of multidrug-resistant hospital outbreaks of *Klebsiella pneumoniae*. *EMBO Mol Med*. 2015;7: 227–239.

28. Campos AC, Albiero J, Ecker AB, Kuroda CM, Meirelles LEF, Polato A, et al. Outbreak of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: A systematic review. *Am J Infect Control*. 2016;44: 1374–1380.

29. Ko W-C, Paterson DL, Sagnimeni AJ, Hansen DS, Von Gottberg A, Mohapatra S, et al. Community-acquired *Klebsiella pneumoniae* bacteremia: global differences in clinical patterns. *Emerg Infect Dis*. 2002;8: 160–166.

30. Shon AS, Bajwa RPS, Russo TA. Hypervirulent (hypermucoviscous) *Klebsiella pneumoniae*: a new and dangerous breed. *Virulence*. 2013;4: 107–118.

31. Struve C, Roe CC, Stegger M, Stahlhut SG, Hansen DS, Engelthaler DM, et al. Mapping the Evolution of Hypervirulent *Klebsiella pneumoniae. MBio.* 2015;6: e00630.

32. Pomakova DK, Hsiao C-B, Beanan JM, Olson R, MacDonald U, Keynan Y, et al. Clinical and phenotypic differences between classic and hypervirulent *Klebsiella pneumonia*: an emerging and under-recognized pathogenic variant. *Eur J Clin Microbiol Infect Dis.* 2012;31: 981–989.

33. Long SW, Linson SE, Ojeda Saavedra M, Cantu C, Davis JJ, Brettin T, et al. Whole-Genome Sequencing of Human Clinical *Klebsiella pneumoniae* Isolates Reveals Misidentification and Misunderstandings of *Klebsiella pneumoniae*, *Klebsiella variicola*, and *Klebsiella quasipneumoniae*. *mSphere. 2017;2(4):e00290-17.*

34. Berry GJ, Loeffelholz MJ, Williams-Bouyer N. An Investigation into Laboratory Misidentification of a Bloodstream *Klebsiella variicola* Infection. *J Clin Microbiol.* 2015;53: 2793–2794.

35. Maatallah M, Vading M, Kabir MH, Bakhrouf A, Kalin M, Nauclér P, et al. *Klebsiella variicola* is a frequent cause of bloodstream infection in the Stockholm area, and associated with higher mortality compared to *K. pneumoniae. PLoS One.* 2014;9: e113539.

36. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic of carbapenem-resistant *Klebsiella pneumoniae* in Europe is driven by nosocomial spread. *Nat Microbiol.* 2019;4: 1919–1929.

37. Ellington MJ, Heinz E, Wailan AM, Dorman MJ, de Goffau M, Cain AK, et al. Contrasting patterns of longitudinal population dynamics and antimicrobial resistance mechanisms in two priority bacterial pathogens over 7 years in a single center. *Genome Biol.* 2019;20: 184.

38. Breurec S, Melot B, Hoen B, Passet V, Schepers K, Bastian S, et al. Liver Abscess Caused by Infection with Community-Acquired *Klebsiella quasipneumoniae* subsp. *quasipneumoniae. Emerg Infect Dis*. 2016;22: 529–531.

39. Harada S, Aoki K, Yamamoto S, Ishii Y, Sekiya N, Kurai H, et al. Clinical and Molecular Characteristics of *Klebsiella pneumoniae* Isolates Causing Bloodstream Infections in Japan: Occurrence of Hypervirulent Infections in Health Care. *J Clin Microbiol.* 2019;57.

40. Shankar C, Veeraraghavan B, Nabarro LEB, Ravi R, Ragupathi NKD, Rupali P. Whole genome analysis of hypervirulent *Klebsiella pneumoniae* isolates from community and hospital acquired bloodstream infection. *BMC Microbiol.* 2018;18: 6.

41. O'neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. *Rev Antimicrob Resist.* 2014;20: 1–16.

42. Chen L, Todd R, Kiehlbauch J, Walters M, Kallen A. Notes from the Field: Pan-Resistant New Delhi Metallo-Beta-Lactamase-Producing *Klebsiella pneumoniae* - Washoe County, Nevada, 2016. *MMWR Morb Mortal Wkly Rep.* 2017;66: 33.

43. Bathoorn E, Tsioutis C, da Silva Voorham JM, Scoulica EV, Ioannidou E, Zhou K, et al. Emergence of pan-resistance in KPC-2 carbapenemase-producing *Klebsiella pneumoniae* in Crete, Greece: a close call. *J Antimicrob Chemother*. 2016;71: 1207–

1212.

44. Sonnevend Á, Ghazawi A, Hashmey R. Multihospital occurrence of pan-resistant *Klebsiella pneumoniae* sequence type 147 with an IS*Ecp1*-directed *bla*OXA-181 insertion in the *mgrB* gene in the United Arab Emirates. *Antimicrob Agents Chemother*. 2017; 61(7): e00418-17.

45. Lee C-R, Lee JH, Park KS, Jeon JH, Kim YB, Cha C-J, et al. Antimicrobial Resistance of Hypervirulent *Klebsiella pneumoniae*: Epidemiology, Hypervirulence-Associated Determinants, and Resistance Mechanisms. *Front Cell Infect Microbiol*. 2017;7: 483.

46. Wyres KL, Wick RR, Judd LM, Froumine R, Tokolyi A, Gorrie CL, et al. Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of *Klebsiella pneumoniae*. *PLoS Genet*. 2019;15: e1008114.

47. Zhang R, Lin D, Chan EW-C, Gu D, Chen G-X, Chen S. Emergence of Carbapenem-Resistant Serotype K1 Hypervirulent *Klebsiella pneumoniae* Strains in China. *Antimicrob Agents Chemother*. 2016;60: 709–711.

48. Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent *Klebsiella pneumoniae* in a Chinese hospital: a molecular epidemiological study. *Lancet Infect Dis.* 2018;18: 37–46.

49. Brockhurst MA, Harrison E, Hall JPJ, Richards T, McNally A, MacLean C. The Ecology and Evolution of Pangenomes. *Curr Biol.* 2019;29: R1094–R1103.

50. Richter M, Rosselló-Móra R. Shifting the genomic gold standard for the prokaryotic species definition. *Proc Natl Acad Sci U S A*. 2009;106: 19126–19131.

51. Shen P, Huang HV. Homologous recombination in *Escherichia coli*: dependence on substrate length and homology. *Genetics*. 1986;112(3):441-457.

52. Paczosa MK, Mecsas J. *Klebsiella pneumoniae*: Going on the Offense with a Strong Defense. *Microbiol Mol Biol Rev.* 2016;80: 629–661.

53. Simoons-Smit AM, Verweij-van Vught AM, MacLaren DM. The role of K antigens as virulence factors in *Klebsiella*. *J Med Microbiol*. 1986;21: 133–137.

54. Follador R, Heinz E, Wyres KL, Ellington MJ, Kowarik M, Holt KE, et al. The diversity of *Klebsiella pneumoniae* surface polysaccharides. *Microb Genom*. 2016;2: e000073.

55. Tomás JM, Benedí VJ, Ciurana B, Jofre J. Role of capsule and O antigen in resistance of *Klebsiella pneumoniae* to serum bactericidal activity. *Infect Immun.* 1986;54: 85–89.

56. Murphy CN, Mortensen MS, Krogfelt KA, Clegg S. Role of *Klebsiella pneumoniae* type 1 and type 3 fimbriae in colonizing silicone tubes implanted into the bladders of mice as a model of catheter-associated urinary tract infections. *Infect Immun.* 2013;81: 3009–3017.

57. Struve C, Bojer M, Krogfelt KA. Characterization of *Klebsiella pneumoniae* type 1 fimbriae by detection of phase variation during colonization and infection and impact on virulence. *Infect Immun.* 2008;76: 4055–4065.

58. Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA. Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) *Klebsiella pneumoniae* ex vivo and in vivo. *Infect Immun.* 2015;83: 3325–3333.

59. Lam MMC, Wyres KL, Judd LM, Wick RR, Jenney A, Brisse S, et al. Tracking key virulence loci encoding aerobactin and salmochelin siderophore synthesis in *Klebsiella pneumoniae. Genome Med.* 2018;10: 77.

60. Fu Y, Guo L, Xu Y, Zhang W, Gu J, Xu J, et al. Alteration of GyrA amino acid required for ciprofloxacin resistance *in Klebsiella pneumoniae* isolates in China. *Antimicrob Agents Chemother.* 2008;52: 2980–2983.

61. Chen F-J, Lauderdale T-L, Ho M, Lo H-J. The roles of mutations in *gyrA*, *parC*, and *ompK35* in fluoroquinolone resistance in *Klebsiella pneumoniae. Microb Drug Resist.* 2003;9: 265–271.

62. Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, et al. In vivo emergence of colistin resistance in *Klebsiella pneumoniae* producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP *mgrB* regulator. *Antimicrob Agents Chemother.* 2013;57: 5521–5526.

63. Jayol A, Poirel L, Brink A, Villegas M-V, Yilmaz M, Nordmann P. Resistance to colistin associated with a single amino acid change in protein PmrB among *Klebsiella pneumoniae* isolates of worldwide origin. *Antimicrob Agents Chemother.* 2014;58: 4762–4766.

64. Poirel L, Jayol A, Bontron S, Villegas M-V, Ozdamar M, Türkoglu S, et al. The *mgrB* gene as a key target for acquired resistance to colistin in *Klebsiella pneumoniae. J Antimicrob Chemother.* 2015;70: 75–80.

65. Groisman EA. The pleiotropic two-component regulatory system PhoP-PhoQ. *J Bacteriol. 2001*;183: 1835–1842.

66. Lee C-R, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global Dissemination of Carbapenemase-Producing *Klebsiella pneumoniae*: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. *Front Microbiol.* 2016;7: 895.

67. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis.* 2016;16: 161–168.

68. Gu D-X, Huang Y-L, Ma J-H, Zhou H-W, Fang Y, Cai J-C, et al. Detection of Colistin Resistance Gene *mcr-1* in Hypervirulent *Klebsiella pneumoniae* and *Escherichia coli* Isolates from an Infant with Diarrhea in China. *Antimicrob Agents Chemother.* 2016;60: 5099–5100.

69. Pfeiffer A. Th. Eseherich. die Darmbakterien des Neugeboreiien und Säuglings. *DMW - Deutsche Medizinische Wochenschrift.* 1885: 740–741.

70. Blount ZD. The unexhausted potential of *E. coli. Elife*. 2015;4: e05826.

71. Fratamico PM, DebRoy C, Liu Y, Needleman DS, Baranzoni GM, Feng P. Advances in Molecular Serotyping and Subtyping of *Escherichia coli. Front Microbiol.* 2016;7: 644.

72. Orskov I, Orskov F, Jann B, Jann K. Serology, chemistry, and genetics of O and K antigens of *Escherichia coli. Bacteriol Rev.* 1977;41: 667–710.

73. Lim JY, Yoon J, Hovde CJ. A brief overview of *Escherichia coli* O157:H7 and its plasmid O157. *J Microbiol Biotechnol.* 2010;20: 5–14.

74. Muniesa M, Hammerl JA, Hertwig S, Appel B, Brüssow H. Shiga toxin-producing

Escherichia coli O104:H4: a new challenge for microbiology. *Appl Environ Microbiol.* 2012;78: 4065–4073.

75. Chaudhuri RR, Henderson IR. The evolution of the *Escherichia coli* phylogeny. *Infect Genet Evol.* 2012;12: 214–226.

76. Reid SD, Herbelin CJ, Bumbaugh AC, Selander RK, Whittam TS. Parallel evolution of virulence in pathogenic *Escherichia coli. Nature.* 2000;406: 64–67.

77. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, et al. Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol Microbiol.* 2006;60: 1136–1151.

78. Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, et al. Phylogenetic and genomic diversity of human bacteremic *Escherichia coli* strains. *BMC Genomics.* 2008;9: 560.

79. Clermont O, Gordon D, Denamur E. Guide to the various phylogenetic classification schemes for *Escherichia coli* and the correspondence among schemes. *Microbiology.* 2015;161: 980–988.

80. Jolley KA, Maiden MCJ. BIGSdb: Scalable analysis of bacterial genome variation at the population level. *BMC Bioinformatics.* 2010;11: 595.

81. Selander RK, Caugant DA, Ochman H, Musser JM, Gilmour MN, Whittam TS. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. *Appl Environ Microbiol.* 1986;51: 873–884.

82. Milkman R. Electrophoretic variation in *Escherichia coli* from natural sources. *Science.* 1973;182: 1024–1026.

83. Selander RK, Levin BR. Genetic diversity and structure in *Escherichia coli* populations. *Science.* 1980;210: 545–547.

84. Whittam TS, Ochman H, Selander RK. Multilocus genetic structure in natural populations of *Escherichia coli. Proc Natl Acad Sci U S A*. 1983;80: 1751–1755.

85. Ochman H, Selander RK. Standard reference strains of *Escherichia coli* from natural populations. *J Bacteriol.* 1984;157: 690–693.

86. Selander RK, Caugant DA, Whittam TS. Genetic structure and variation in natural populations of *Escherichia coli*. Escherichia coli *and* Salmonella typhimurium*: Cellular and Molecular Biology, vol 2*. Washington, D.C.: American Society for Microbiology. 1987: 1625–1648.

87. Herzer PJ, Inouye S, Inouye M, Whittam TS. Phylogenetic distribution of branched RNA-linked multicopy single-stranded DNA among natural isolates of *Escherichia coli. J Bacteriol.* 1990;172: 6175–6181.

88. Clermont O, Olier M, Hoede C, Diancourt L, Brisse S, Keroudean M, et al. Animal and human pathogenic *Escherichia coli* strains share common genetic backgrounds. *Infect Genet Evol.* 2011;11: 654–662.

89. Clermont O, Dixit OVA, Vangchhia B, Condamine B, Dion S, Bridier-Nahmias A, et al. Characterization and rapid identification of phylogroup G in *Escherichia coli*, a lineage with high virulence and antibiotic resistance potential. *Environ Microbiol.* 2019;21: 3107–3117.

90. Walk ST. The "Cryptic" *Escherichia. EcoSal Plus.* 2015;6

91. Clermont O, Gordon DM, Brisse S, Walk ST, Denamur E. Characterization of the cryptic *Escherichia* lineages: rapid identification and prevalence. *Environ Microbiol.* 2011;13: 2468–2477.

92. Abram KZ, Udaondo Z, Bleker C, Wanchai V. What can we learn from over 100,000 *Escherichia coli* genomes? *bioRxiv.* 2020; 708131; doi: https://doi.org/10.1101/708131

93. Zhou Z, Alikhan N-F, Mohamed K, Fan Y, Agama Study Group, Achtman M. The EnteroBase user's guide, with case studies on *Salmonella* transmissions, *Yersinia pestis* phylogeny, and *Escherichia* core genomic diversity. *Genome Res.* 2020;30: 138–152.

94. Sabarly V, Bouvet O, Glodt J, Clermont O, Skurnik D, Diancourt L, et al. The decoupling between genetic structure and metabolic phenotypes in *Escherichia coli* leads to continuous phenotypic diversity. *J Evol Biol.* 2011;24: 1559–1571.

95. Beghain J, Bridier-Nahmias A, Le Nagard H, Denamur E, Clermont O. ClermonTyping: an easy-to-use and accurate *in silico* method for *Escherichia* genus strain phylotyping. *Microb Genom.* 2018;4.

96. Shiga K. Sekiri byogen kenkyu hokoku dai-ichi (first report on etiologic research on dysentery). *Saikingaku Zasshi.* 1897;25: 790.

97. Ewing WH, Starr MP. Edwards and Ewing's Identification of Enterobacteriaceae: Fourth Edition. *International Journal of Systematic and Evolutionary Microbiology.* 1986;36(4): 581-582

98. Beld MJC, Reubsaet FAG. Differentiation between *Shigella*, enteroinvasive *Escherichia coli* (EIEC) and noninvasive *Escherichia coli. EJCMID.* 2012. pp. 899–904.

99. Pettengill EA, Pettengill JB, Binet R. Phylogenetic Analyses of *Shigella* and Enteroinvasive *Escherichia coli* for the Identification of Molecular Epidemiological Markers: Whole-Genome Comparative Analysis Does Not Support Distinct Genera Designation. *Front Microbiol.* 2015;6: 1573.

100. Chattaway MA, Schaefer U, Tewolde R, Dallman TJ, Jenkins C. Identification of *Escherichia coli* and *Shigella* Species from Whole-Genome Sequences. *J Clin Microbiol.* 2017;55: 616–623.

101. Croxen MA, Finlay BB. Molecular mechanisms of *Escherichia coli* pathogenicity. *Nat Rev Microbiol.* 2010;8: 26–38.

102. Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. Recent advances in understanding enteric pathogenic *Escherichia coli. Clin Microbiol Rev.* 2013;26: 822–880.

103. Ochoa TJ, Contreras CA. Enteropathogenic *Escherichia coli* infection in children. *Curr Opin Infect Dis.* 2011. pp. 478–483.

104. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet.* 2013;382: 209–222.

105. de la Cabada Bauche J, Dupont HL. New Developments in Traveler's Diarrhea.

Gastroenterol Hepatol. 2011;7: 88–95.

106.   Nguyen Y, Sperandio V. Enterohemorrhagic *E. coli* (EHEC) pathogenesis. *Front Cell Infect Microbiol*. 2012;2: 90.

107.   Dean-Nystrom EA, Bosworth BT, Moon HW. Pathogenesis of *Escherichia coli* O157:H7 in weaned calves. *Adv Exp Med Biol*. 1999;473: 173-177.

108.   Burger R. EHEC O104:H4 IN GERMANY 2011: LARGE OUTBREAK OF BLOODY DIARRHEA AND HAEMOLYTIC URAEMIC SYNDROME BY SHIGA TOXIN– PRODUCING E. COLI VIA CONTAMINATED FOOD. *Improving Food Safety Through a One Health Approach: Workshop Summary*. Washington (DC): National Academies Press (US); 2012.

109.   McLellan LK, Hunstad DA. Urinary Tract Infection: Pathogenesis and Outlook. *Trends Mol Med.* 2016;22: 946–957.

110.   de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. *Clin Microbiol Infect*. 2013;19: 860–868.

111.   Laupland KB. Incidence of bloodstream infection: a review of population-based studies. *Clin Microbiol Infect*. 2013;19: 492–500.

112.   Asadi Karam MR, Habibi M, Bouzari S. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic *Escherichia coli. Mol Immunol.* 2019;108: 56–67.

113.   Vihta K-D, Stoesser N, Llewelyn MJ, Quan TP, Davies T, Fawcett NJ, et al. Trends over time in *Escherichia coli* bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998-2016: a study of electronic health records. *Lancet Infect Dis.* 2018;18: 1138–1149.

114.   Pupo GM, Karaolis DK, Lan R, Reeves PR. Evolutionary relationships among pathogenic and nonpathogenic *Escherichia coli* strains inferred from multilocus enzyme electrophoresis and *mdh* sequence studies. *Infect Immun.* 1997;65: 2685–2692.

115.   Hazen TH, Donnenberg MS, Panchalingam S, Antonio M, Hossain A, Mandomando I, et al. Genomic diversity of EPEC associated with clinical presentations of differing severity. *Nat Microbiol.* 2016;1: 15014.

116.   Hazen TH, Sahl JW, Fraser CM, Donnenberg MS, Scheutz F, Rasko DA. Refining the pathovar paradigm via phylogenomics of the attaching and effacing *Escherichia coli. Proc Natl Acad Sci U S A*. 2013;110: 12810–12815.

117.   von Mentzer A, Connor TR, Wieler LH, Semmler T, Iguchi A, Thomson NR, et al. Identification of enterotoxigenic *Escherichia coli* (ETEC) clades with long-term global distribution. *Nat Genet.* 2014;46: 1321–1326.

118.   Rasko DA, Del Canto F, Luo Q, Fleckenstein JM, Vidal R, Hazen TH. Comparative genomic analysis and molecular examination of the diversity of enterotoxigenic *Escherichia coli* isolates from Chile. *PLoS Negl Trop Dis*. 2019;13: e0007828.

119.   Ingle DJ, Tauschek M, Edwards DJ, Hocking DM, Pickard DJ, Azzopardi KI, et al. Evolution of atypical enteropathogenic *E. coli* by repeated acquisition of LEE pathogenicity island variants. *Nat Microbiol.* 2016;1: 15010.

120.   Kallonen T, Brodrick HJ, Harris SR, Corander J, Brown NM, Martin V, et al. Systematic longitudinal survey of invasive *Escherichia coli* in England demonstrates a stable population structure only transiently disturbed by the emergence of ST131. *Genome Res*. 2017 18;27(8):1437-1449.

121.   Salipante SJ, Roach DJ, Kitzman JO, Snyder MW, Stackhouse B, Butler-Wu SM, et al. Large-scale genomic sequencing of extraintestinal pathogenic *Escherichia coli* strains. *Genome Res*. 2015;25: 119–128.

122.   Riley LW. Pandemic lineages of extraintestinal pathogenic *Escherichia coli. Clin Microbiol Infect.* 2014;20: 380–390.

123.   Morfin-Otero R, Noriega ER, Dowzicky MJ. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial. *Ann Clin Microbiol Antimicrob.* 2015;14: 53.

124.   Jones RN, Guzman-Blanco M, Gales AC, Gallegos B, Castro ALL, Martino MDV, et al. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). *Braz J Infect Dis*. 2013;17: 672–681.

125.   Sharma M. Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing *Escherichia coli* and *Klebsiella* spp. *J Clin Diagn Res*. 2013;7(10):2173-2177.

126.   Cornejo-Juárez P, Vilar-Compte D, García-Horton A, López-Velázquez M, Ñamendys-Silva S, Volkow-Fernández P. Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients. *BMC Infect Dis*. 2016;16: 274.

127.   Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. *Int J Antimicrob Agents*. 2017;50: 127–134.

128.   Tang H-J, Hsieh C-F, Chang P-C, Chen J-J, Lin Y-H, Lai C-C, et al. Clinical Significance of Community- and Healthcare-Acquired Carbapenem-Resistant Enterobacteriaceae Isolates. *PLoS One*. 2016. p. e0151897.

129.   Brennan BM, Coyle JR, Marchaim D, Pogue JM, Boehme M, Finks J, et al. Statewide surveillance of carbapenem-resistant Enterobacteriaceae in Michigan. *Infect Control Hosp Epidemiol.* 2014;35: 342–349.

130.   Wang R, Liu Y, Zhang Q, Jin L, Wang Q, Zhang Y, et al. The prevalence of colistin resistance in *Escherichia coli* and *Klebsiella pneumoniae* isolated from food animals in China: coexistence of *mcr-1* and *bla*NDM with low fitness cost. *Int J Antimicrob Agents.* 2018;51: 739–744.

131.   Yamamoto Y, Kawahara R, Fujiya Y, Sasaki T, Hirai I, Khong DT, et al. Wide dissemination of colistin-resistant *Escherichia coli* with the mobile resistance gene *mcr* in healthy residents in Vietnam. *J Antimicrob Chemother*. 2019;74: 523–524.

132.   Blango MG, Mulvey MA. Persistence of uropathogenic *Escherichia coli* in the face of multiple antibiotics. *Antimicrob Agents Chemother*. 2010;54: 1855–1863.

133.   Pitout JDD, DeVinney R. *Escherichia coli* ST131: a multidrug-resistant clone primed for global domination. *F1000Res*. 2017;6. doi:10.12688/f1000research.10609.1

134. Roer L, Overballe-Petersen S, Hansen F, Schønning K, Wang M, Røder BL, et al. *Escherichia coli* Sequence Type 410 Is Causing New International High-Risk Clones. *mSphere*. 2018;3.

135. Feng Y, Liu L, Lin J, Ma K, Long H, Wei L, et al. Key evolutionary events in the emergence of a globally disseminated, carbapenem resistant clone in *the Escherichia coli* ST410 lineage. *Commun Biol*. 2019;2: 322.

136. Bajaj P, Singh NS, Virdi JS. *Escherichia coli* β-Lactamases: What Really Matters. *Front Microbiol*. 2016;7: 417.

137. Scaletsky ICA, Souza TB, Aranda KRS, Okeke IN. Genetic elements associated with antimicrobial resistance in enteropathogenic *Escherichia coli* (EPEC) from Brazil. *BMC Microbiol*. 2010;10: 25.

138. Senerwa D, Mutanda LN, Gathuma JM, Olsvik O. Antimicrobial resistance of enteropathogenic *Escherichia coli* strains from a nosocomial outbreak in Kenya. *APMIS*. 1991;99: 728–734.

139. Xu Y, Sun H, Bai X, Fu S, Fan R, Xiong Y. Occurrence of multidrug-resistant and ESBL-producing atypical enteropathogenic *Escherichia coli* in China. *Gut Pathog.* 2018;10: 8.

140. Goyal D, Dean N, Neill S, Jones P, Dascomb K. Risk Factors for Community-Acquired Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections-A Retrospective Study of Symptomatic Urinary Tract Infections. *Open Forum Infect Dis.* 2019;6: ofy357.

141. Koksal E, Tulek N, Sonmezer MC, Temocin F, Bulut C, Hatipoglu C, et al. Investigation of risk factors for community-acquired urinary tract infections caused by extended-spectrum beta-lactamase *Escherichia coli* and *Klebsiella* species. *Investig Clin Urol.* 2019;60: 46–53.

142. Malvi S, Kumar Y, Appannanavar S, Gautam N, Taneja N, Kaur H, et al. Comparative analysis of virulence determinants, antibiotic susceptibility patterns and serogrouping of atypical enteropathogenic *Escherichia coli* versus typical enteropathogenic *E. coli* in India. *Journal of Medical Microbiology*. 2015. pp. 1208–1215.

143. Zhou Y, Zhu X, Hou H, Lu Y, Yu J, Mao L, et al. Characteristics of diarrheagenic *Escherichia coli* among children under 5 years of age with acute diarrhea: a hospital based study. *BMC Infect Dis.* 2018;18: 63.

144. Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, et al. The complete genome sequence of *Escherichia coli* K-12. *Science*. 1997;277: 1453–1462.

145. Hayashi T. Complete Genome Sequence of Enterohemorrhagic *Escherichia coli* O157:H7 and Genomic Comparison with a Laboratory Strain K-12 (Supplement). *DNA Research.* 2001. pp. 47–52.

146. Welch RA, Burland V, Plunkett G 3rd, Redford P, Roesch P, Rasko D, et al. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic *Escherichia coli*. *Proc Natl Acad Sci U S A*. 2002;99: 17020–17024.

147. Rasko DA, Rosovitz MJ, Myers GSA, Mongodin EF, Fricke WF, Gajer P, et al. The pangenome structure of *Escherichia coli*: comparative genomic analysis of *E. coli*

commensal and pathogenic isolates. *J Bacteriol*. 2008;190: 6881–6893.

148.   Gordienko EN, Kazanov MD, Gelfand MS. Evolution of pan-genomes of *Escherichia coli, Shigella* spp., and *Salmonella enterica. J Bacteriol*. 2013;195: 2786–2792.

149.   Robins-Browne RM, Holt KE, Ingle DJ, Hocking DM, Yang J, Tauschek M. Are *Escherichia coli* Pathotypes Still Relevant in the Era of Whole-Genome Sequencing? *Front Cell Infect Microbiol*. 2016;6: 141.

150.   McDaniel TK, Kaper JB. A cloned pathogenicity island from enteropathogenic *Escherichia coli* confers the attaching and effacing phenotype on *E. coli* K-12. *Mol Microbiol*. 1997;23: 399–407.

151.   Kenny B, DeVinney R, Stein M, Reinscheid DJ, Frey EA, Finlay BB. Enteropathogenic *E. coli* (EPEC) transfers its receptor for intimate adherence into mammalian cells. *Cell.* 1997;91: 511–520.

152.   Tacket CO, Sztein MB, Losonsky G, Abe A. Role of EspB in Experimental Human Enteropathogenic *Escherichia coli* Infection. *Infection and immunity*. 2000; 68(6): 3689–3695.

153.   Girón JA, Ho AS, Schoolnik GK. An inducible bundle-forming pilus of enteropathogenic *Escherichia coli. Science*. 1991;254: 710–713.

154.   Tennant SM, Tauschek M, Azzopardi K, Bigham A, Bennett-Wood V, Hartland EL, et al. Characterisation of atypical enteropathogenic *E. coli* strains of clinical origin. BMC *Microbiol*. 2009;9: 117.

155.   Lee M-S, Cherla RP, Tesh VL. Shiga toxins: intracellular trafficking to the ER leading to activation of host cell stress responses. *Toxins* . 2010;2: 1515–1535.

156.   McWilliams BD, Torres AG. Enterohemorrhagic *Escherichia coli* Adhesins. Microbiology Spectrum. *Microbiol Spectr*. 2014;2(3):10.1128/microbiolspec.EHEC-0003-2013.

157.   Sears CL, Kaper JB. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. *Microbiol Rev.* 1996;60(1):167-215.

158.   Nataro JP, Kaper JB, Robins-Browne R, Prado V, Vial P, Levine MM. Patterns of adherence of diarrheagenic *Escherichia coli* to HEp-2 cells. *Pediatr Infect Dis J.* 1987;6: 829–831.

159.   Panchalingam S, Antonio M, Hossain A, Mandomando I, Ochieng B, Oundo J, et al. Diagnostic microbiologic methods in the GEMS-1 case/control study. *Clin Infect Dis.* 2012;55 Suppl 4: S294–302.

160.   Scaletsky IC, Silva ML, Trabulsi LR. Distinctive patterns of adherence of enteropathogenic *Escherichia coli* to HeLa cells. *Infect Immun.* 1984;45: 534–536.

161.   Servin AL. Pathogenesis of Human Diffusely Adhering *Escherichia coli* Expressing Afa/Dr Adhesins (Afa/Dr DAEC): Current Insights and Future Challenges. *Clin Microbiol Rev.* 2014;27(4):823-869.

162.   Schroeder GN, Hilbi H. Molecular pathogenesis of *Shigella* spp.: controlling host cell signaling, invasion, and death by type III secretion. *Clin Microbiol Rev*. 2008;21: 134–

156.

163.   Pupo GM, Lan R, Reeves PR. Multiple independent origins of *Shigella* clones of *Escherichia coli* and convergent evolution of many of their characteristics. *Proc Natl Acad Sci U S A*. 2000;97: 10567–10572.

164.   Köhler C-D, Dobrindt U. What defines extraintestinal pathogenic *Escherichia coli*? *Int J Med Microbiol*. 2011;301: 642–647.

165.   Pitout JDD. Extraintestinal Pathogenic *Escherichia coli*: A Combination of Virulence with Antibiotic Resistance. *Front Microbiol.* 2012;3:9.

166.   Galardini M, Clermont O, Baron A, Busby B, Dion S, Schubert S, et al. Major role of iron uptake systems in the intrinsic extra-intestinal virulence of the genus *Escherichia* revealed by a genome-wide association study. *bioRxiv*. 2020; 712034. doi:10.1101/712034

167.   Brzuszkiewicz E, Thürmer A, Schuldes J, Leimbach A, Liesegang H, Meyer F-D, et al. Genome sequence analyses of two isolates from the recent *Escherichia coli* outbreak in Germany reveal the emergence of a new pathotype: Entero-Aggregative-Haemorrhagic *Escherichia coli* (EAHEC). *Arch Microbiol*. 2011;193: 883–891.

168.   Carattoli A. Plasmids and the spread of resistance. *Int J Med Microbiol*. 2013;303: 298–304.

169.   Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L. Mechanisms accounting for fluoroquinolone resistance in *Escherichia coli* clinical isolates. *Antimicrob Agents Chemother.* 2009;53: 235–241.

170.   Olaitan AO, Morand S, Rolain J-M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol.* 2014;5: 643.

171.   Jacoby GA. AmpC β-Lactamases. *Clinical Microbiology Reviews*. 2009. pp. 161–182.

172.   Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. *J Antimicrob Chemother*. 2007;59: 165–174.

173.   Nicolas-Chanoine M-H, Bertrand X, Madec J-Y. *Escherichia coli* ST131, an intriguing clonal group. *Clin Microbiol Rev*. 2014;27: 543–574.

174.   Brodrick HJ, Raven KE, Kallonen T, Jamrozy D, Blane B, Brown NM, et al. Longitudinal genomic surveillance of multidrug-resistant *Escherichia coli* carriage in a long-term care facility in the United Kingdom. *Genome Med*. 2017;9: 70.

175.   Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-β-lactamase (NDM): a threat to public health. *BMC Microbiol*. 2017;17: 101.

176.   Hammerl JA, Borowiak M, Schmoger S, Shamoun D, Grobbel M, Malorny B, et al. *mcr-5* and a novel *mcr-5.2* variant in *Escherichia coli* isolates from food and food-producing animals, Germany, 2010 to 2017. *J Antimicrob Chemother*. 2018;73: 1433–1435.

177.   Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P, Goossens H, et al. Identification of a novel plasmid-mediated colistin-resistance gene, *mcr-2*, in *Escherichia coli,* Belgium, June 2016. *Euro Surveill*. 2016; 7;21(27). doi: 10.2807/1560-

7917.ES.2016.21.27.30280. Erratum in: *Euro Surveill. 2016 14;21(28): PMID: 27416987.*

178.   Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z, et al. Novel Plasmid-Mediated Colistin Resistance Gene *mcr-3* in *Escherichia coli. MBio*. 2017;8.

179.   Carattoli A, Villa L, Feudi C, Curcio L, Orsini S, Luppi A, et al. Novel plasmid-mediated colistin resistance *mcr-4* gene in *Salmonella* and *Escherichia coli*, Italy 2013, Spain and Belgium, 2015 to 2016. *Euro Surveill*. 2017;22. doi:10.2807/1560-7917.ES.2017.22.31.30589

180.   Sun J, Zhang H, Liu Y-H, Feng Y. Towards Understanding MCR-like Colistin Resistance. *Trends Microbiol*. 2018;26: 794–808.

181.   Soucy SM, Huang J, Gogarten JP. Horizontal gene transfer: building the web of life. *Nat Rev Genet*. 2015;16: 472–482.

182.   Treangen TJ, Rocha EPC. Horizontal transfer, not duplication, drives the expansion of protein families in prokaryotes. *PLoS Genet*. 2011;7: e1001284.

183.   Delavat F, Miyazaki R, Carraro N, Pradervand N, van der Meer JR. The hidden life of integrative and conjugative elements. *FEMS Microbiol Rev*. 2017;41: 512–537.

184.   von Wintersdorff CJH, Penders J, van Niekerk JM, Mills ND, Majumder S, van Alphen LB, et al. Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer. *Front Microbiol*. 2016;7: 173.

185.   Thomas CM, Nielsen KM. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. *Nat Rev Microbiol*. 2005;3: 711–721.

186.   Christie PJ. Type IV secretion: intercellular transfer of macromolecules by systems ancestrally related to conjugation machines. *Mol Microbiol*. 2001;40: 294–305.

187.   Smillie C, Garcillán-Barcia MP, Francia MV, Rocha EPC, de la Cruz F. Mobility of plasmids. *Microbiol Mol Biol Rev*. 2010;74: 434–452.

188.   Wong JJW, Lu J, Glover JNM. Relaxosome function and conjugation regulation in F-like plasmids - a structural biology perspective. *Mol Microbiol*. 2012;85: 602–617.

189.   Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile Genetic Elements Associated with Antimicrobial Resistance. *Clin Microbiol Rev*. 2018;31.

190.   Mell JC, Redfield RJ. Natural competence and the evolution of DNA uptake specificity. *J Bacteriol*. 2014;196: 1471–1483.

191.   Frost LS, Leplae R, Summers AO, Toussaint A. Mobile genetic elements: the agents of open source evolution. *Nat Rev Microbiol*. 2005;3: 722–732.

192.   Didelot X, Maiden MCJ. Impact of recombination on bacterial evolution. *Trends Microbiol*. 2010;18: 315–322.

193.   Chen Z, Yang H, Pavletich NP. Mechanism of homologous recombination from the RecA-ssDNA/dsDNA structures. *Nature*. 2008;453: 489–484.

194.   Vos M, Didelot X. A comparison of homologous recombination rates in bacteria and archaea. *ISME J.* 2009;3: 199–208.

195.   Siguier P, Gourbeyre E, Varani A, Ton-Hoang B, Chandler M. Everyman's Guide to Bacterial Insertion Sequences. *Microbiol Spectr*. 2015;3: MDNA3–0030–2014.

196.   Gillings MR. Integrons: past, present, and future. *Microbiol Mol Biol Rev*. 2014;78: 257–277.

197.   Treangen TJ, Salzberg SL. Repetitive DNA and next-generation sequencing: computational challenges and solutions. *Nat Rev Genet*. 2011;13: 36–46.

198.   Watt VM, Ingles CJ, Urdea MS, Rutter WJ. Homology requirements for recombination in *Escherichia coli*. *Proc Natl Acad Sci U S A*. 1985;82: 4768–4772.

199.   Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Site-Specific Recombination. *Molecular Biology of the Cell. 4th edition.* Garland Science; 2002.

200.   Couturier M, Bex F, Bergquist PL, Maas WK. Identification and classification of bacterial plasmids. *Microbiol Rev.* 1988;52: 375–395.

201.   Rozwandowicz M, Brouwer MSM, Fischer J, Wagenaar JA, Gonzalez-Zorn B, Guerra B, et al. Plasmids carrying antimicrobial resistance genes in Enterobacteriaceae. *J Antimicrob Chemother.* 2018;73: 1121–1137.

202.   Moller AG, Lindsay JA, Read TD. Determinants of Phage Host Range in *Staphylococcus* Species. *Appl Environ Microbiol*. 2019;85.

203.   Abedon ST. Bacterial "immunity" against bacteriophages. *Bacteriophage*. 2012; 50–54.

204.   Hampton HG, Watson BNJ, Fineran PC. The arms race between bacteria and their phage foes. *Nature*. 2020;577: 327–336.

205.   Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. *Science*. 2008;322: 1843–1845.

206.   Popa O, Dagan T. Trends and barriers to lateral gene transfer in prokaryotes. *Curr Opin Microbiol.* 2011;14: 615–623.

207.   Chewapreecha C, Harris SR, Croucher NJ, Turner C, Marttinen P, Cheng L, et al. Dense genomic sampling identifies highways of pneumococcal recombination. *Nat Genet.* 2014;46: 305–309.

208.   Rendueles O, de Sousa JAM, Bernheim A, Touchon M, Rocha EPC. Genetic exchanges are more frequent in bacteria encoding capsules. *PLoS Genet*. 2018;14: e1007862.

209.   Jang J, Hur H-G, Sadowsky MJ, Byappanahalli MN, Yan T, Ishii S. Environmental *Escherichia coli*: ecology and public health implications-a review. *J Appl Microbiol.* 2017;123: 570–581.

210.   Iranzo J, Wolf YI, Koonin EV, Sela I. Gene gain and loss push prokaryotes beyond the homologous recombination barrier and accelerate genome sequence divergence. *Nat Commun*. 2019;10: 5376.

211.   Vos M, Hesselman MC, Te Beek TA, van Passel MWJ, Eyre-Walker A. Rates of Lateral Gene Transfer in Prokaryotes: High but Why? *Trends Microbiol*. 2015;23: 598–605.

212. Didelot X, Méric G, Falush D, Darling AE. Impact of homologous and non-homologous recombination in the genomic evolution of *Escherichia coli. BMC Genomics.* 2012;13: 256.

213. McNally A, Cheng L, Harris SR, Corander J. The evolutionary path to extraintestinal pathogenic, drug-resistant *Escherichia coli* is marked by drastic reduction in detectable recombination within the core genome. *Genome Biol Evol.* 2013;5: 699–710.

214. Chen L, Mathema B, Pitout JDD, DeLeo FR, Kreiswirth BN. Epidemic *Klebsiella pneumoniae* ST258 is a hybrid strain. *MBio.* 2014;5: e01355–14.

215. Comandatore F, Sassera D, Bayliss SC, Scaltriti E, Gaiarsa S, Cao X, et al. Gene Composition as a Potential Barrier to Large Recombinations in the Bacterial Pathogen *Klebsiella pneumoniae. Genome Biol Evol.* 2019;11: 3240–3251.

216. Bergthorsson U, Ochman H. Distribution of chromosome length variation in natural isolates of *Escherichia coli. Mol Biol Evol.* 1998;15: 6–16.

217. Bergthorsson U, Ochman H. Heterogeneity of genome sizes among natural isolates of *Escherichia coli. J Bacteriol.* 1995;177: 5784–5789.

218. Marsh JW, Mustapha MM, Griffith MP, Evans DR, Ezeonwuka C, Pasculle AW, et al. Evolution of Outbreak-Causing Carbapenem-Resistant *Klebsiella pneumoniae* ST258 at a Tertiary Care Hospital over 8 Years. *MBio.* 2019;10.

219. Lin Y-C, Lu M-C, Tang H-L, Liu H-C, Chen C-H, Liu K-S, et al. Assessment of hypermucoviscosity as a virulence factor for experimental *Klebsiella pneumoniae* infections: comparative virulence analysis with hypermucoviscosity-negative strain. *BMC Microbiol.* 2011;11: 50.

220. Lin T-L, Lee C-Z, Hsieh P-F, Tsai S-F, Wang J-T. Characterization of integrative and conjugative element ICEK*p1*-associated genomic heterogeneity in *a Klebsiella pneumoniae* strain isolated from a primary liver abscess. *J Bacteriol.* 2008;190: 515–526.

221. Acheson DW, Reidl J, Zhang X, Keusch GT, Mekalanos JJ, Waldor MK. *In vivo* transduction with shiga toxin 1-encoding phage. *Infect Immun.* 1998;66: 4496–4498.

222. Datz M, Janetzki-Mittmann C, Franke S, Gunzer F, Schmidt H, Karch H. Analysis of the enterohemorrhagic *Escherichia coli* O157 DNA region containing lambdoid phage gene p and Shiga-like toxin structural genes. *Appl Environ Microbiol.* 1996;62: 791–797.

223. Neely MN, Friedman DI. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. *Molecular Microbiology.* 1998. pp. 1255–1267.

224. Dudley EG, Thomson NR, Parkhill J, Morin NP, Nataro JP. Proteomic and microarray characterization of the AggR regulon identifies a pheU pathogenicity island in enteroaggregative *Escherichia coli. Mol Microbiol.* 2006;61: 1267–1282.

225. Nataro JP, Yikang D, Yingkang D, Walker K. AggR, a transcriptional activator of aggregative adherence fimbria I expression in enteroaggregative *Escherichia coli. J Bacteriol. 1*994;176: 4691–4699.

226. Pilla G, Tang CM. Going around in circles: virulence plasmids in enteric pathogens. *Nat Rev Microbiol.* 2018;16: 484–495.

227.   Lobato-Márquez D, Díaz-Orejas R, García-Del Portillo F. Toxin-antitoxins and bacterial virulence. *FEMS Microbiol Rev.* 2016;40: 592–609.

228.   Brzozowska I, Zielenkiewicz U. Regulation of toxin–antitoxin systems by proteolysis. *Plasmid.* 2013;70: 33–41.

229.   Ogura T, Hiraga S. Mini-F plasmid genes that couple host cell division to plasmid proliferation. *Proc Natl Acad Sci U S A.* 1983;80: 4784–4788.

230.   Gerdes K, Rasmussen PB, Molin S. Unique type of plasmid maintenance function: postsegregational killing of plasmid-free cells. *Proc Natl Acad Sci U S A.* 1986;83: 3116–3120.

231.   Song S, Wood TK. Post-segregational Killing and Phage Inhibition Are Not Mediated by Cell Death Through Toxin/Antitoxin Systems. *Front Microbiol.* 2018;9: 814.

232.   Yang QE, Walsh TR. Toxin-antitoxin systems and their role in disseminating and maintaining antimicrobial resistance. *FEMS Microbiol Rev.* 2017;41: 343–353.

233.   Short FL, Pei XY, Blower TR, Ong S-L, Fineran PC, Luisi BF, et al. Selectivity and self-assembly in the control of a bacterial toxin by an antitoxic noncoding RNA pseudoknot. *Proc Natl Acad Sci U S A.* 2013;110: E241–9.

234.   Masuda H, Tan Q, Awano N, Yamaguchi Y, Inouye M. A novel membrane-bound toxin for cell division, CptA (YgfX), inhibits polymerization of cytoskeleton proteins, FtsZ and MreB, in *Escherichia coli. FEMS Microbiol Lett.* 2012;328: 174–181.

235.   Wang X, Lord DM, Cheng H-Y, Osbourne DO, Hong SH, Sanchez-Torres V, et al. A new type V toxin-antitoxin system where mRNA for toxin GhoT is cleaved by antitoxin GhoS. *Nat Chem Biol.* 2012;8: 855–861.

236.   Aakre CD, Phung TN, Huang D, Laub MT. A bacterial toxin inhibits DNA replication elongation through a direct interaction with the β sliding clamp. *Mol Cell.* 2013;52: 617–628.

237.   Marimon O, Teixeira JMC, Cordeiro TN, Soo VWC, Wood TL, Mayzel M, et al. An oxygen-sensitive toxin–antitoxin system. *Nat Commun.* 2016;7: 13634.

238.   Page R, Peti W. Toxin-antitoxin systems in bacterial growth arrest and persistence. *Nat Chem Biol.* 2016;12: 208–214.

239.   Fozo EM, Hemm MR, Storz G. Small toxic proteins and the antisense RNAs that repress them. *Microbiol Mol Biol Rev.* 2008;72: 579–89.

240.   Dao-Thi M-H, Van Melderen L, De Genst E, Afif H, Buts L, Wyns L, et al. Molecular basis of gyrase poisoning by the addiction toxin CcdB. *J Mol Biol.* 2005;348: 1091–1102.

241.   Jiang Y, Pogliano J, Helinski DR, Konieczny I. ParE toxin encoded by the broad-host-range plasmid RK2 is an inhibitor of *Escherichia coli* gyrase. *Mol Microbiol.* 2002;44: 971–979.

242.   Mutschler H, Meinhart A. ε/ζ systems: their role in resistance, virulence, and their potential for antibiotic development. *J Mol Med .* 2011;89: 1183–1194.

243.   Winther KS, Gerdes K. Enteric virulence associated protein VapC inhibits translation by cleavage of initiator tRNA. *Proc Natl Acad Sci U S A.* 2011;108: 7403–7407.

244. Kaspy I, Rotem E, Weiss N, Ronin I, Balaban NQ, Glaser G. HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase. *Nat Commun*. 2013;4: 3001.

245. Castro-Roa D, Garcia-Pino A, De Gieter S, van Nuland NAJ, Loris R, Zenkin N. The Fic protein Doc uses an inverted substrate to phosphorylate and inactivate EF-Tu. *Nat Chem Biol.* 2013;9: 811–817.

246. Christensen SK, Gerdes K. RelE toxins from bacteria and Archaea cleave mRNAs on translating ribosomes, which are rescued by tmRNA. Mol Microbiol. 2003;48: 1389–1400.

247. Zhang Y, Zhang J, Hoeflich KP, Ikura M, Qing G, Inouye M. MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in *Escherichia coli. Mol Cell.* 2003;12: 913–923.

248. Blower TR, Pei XY, Short FL, Fineran PC, Humphreys DP, Luisi BF, et al. A processed noncoding RNA regulates an altruistic bacterial antiviral system. *Nat Struct Mol Biol.* 2011;18: 185–190.

249. Masuda H, Tan Q, Awano N, Wu K-P, Inouye M. YeeU enhances the bundling of cytoskeletal polymers of MreB and FtsZ, antagonizing the CbtA (YeeV) toxicity in *Escherichia coli. Mol Microbiol.* 2012;84: 979–989.

250. McVicker G, Tang CM. Deletion of toxin–antitoxin systems in the evolution of *Shigella sonnei* as a host-adapted pathogen. *Nat Microbiol.* 2016;2:16204.

251. Makarova KS, Wolf YI, Koonin EV. Comprehensive comparative-genomic analysis of type 2 toxin-antitoxin systems and related mobile stress response systems in prokaryotes. *Biol Direct.* 2009;4: 19.

252. Harms A, Maisonneuve E, Gerdes K. Mechanisms of bacterial persistence during stress and antibiotic exposure. *Science.* 2016;354.

253. Helaine S, Cheverton AM, Watson KG, Faure LM, Matthews SA, Holden DW. Internalization of *Salmonella* by macrophages induces formation of nonreplicating persisters. *Science.* 2014;343: 204–208.

254. Cataudella I, Trusina A, Sneppen K, Gerdes K, Mitarai N. Conditional cooperativity in toxin-antitoxin regulation prevents random toxin activation and promotes fast translational recovery. *Nucleic Acids Res.* 2012;40: 6424–6434.

255. Ramisetty BCM, Santhosh RS. Horizontal gene transfer of chromosomal Type II toxin–antitoxin systems of *Escherichia coli. FEMS Microbiol Lett.* 2016;363.

256. Hazan R, Engelberg-Kulka H. *Escherichia coli* mazEF-mediated cell death as a defense mechanism that inhibits the spread of phage P1. *Molecular Genetics and Genomics.* 2004;227–234.

257. Fineran PC, Blower TR, Foulds IJ, Humphreys DP, Lilley KS, Salmond GPC. The phage abortive infection system, ToxIN, functions as a protein–RNA toxin–antitoxin pair. *Proc Natl Acad Sci U S A.* 2009;106: 894–899.

258. Dy RL, Przybilski R, Semeijn K, Salmond GPC, Fineran PC. A widespread bacteriophage abortive infection system functions through a Type IV toxin–antitoxin mechanism. *Nucleic Acids Res.* 2014;42: 4590–4605.

259.   Wang Y, Wang H, Hay AJ, Zhong Z, Zhu J, Kan B. Functional RelBE-Family Toxin-Antitoxin Pairs Affect Biofilm Maturation and Intestine Colonization in Vibrio cholerae. *PLoS One.* 2015;10: e0135696.

260.   Barrios AFG, Zuo R, Hashimoto Y, Yang L, Bentley WE, Wood TK. Autoinducer 2 controls biofilm formation in *Escherichia coli* through a novel motility quorum-sensing regulator (MqsR, B3022). *J Bacteriol.* 2006;188: 305–316.

261.   Soo VWC, Wood TK. Antitoxin MqsA represses curli formation through the master biofilm regulator CsgD*. Sci Rep.* 2013;3: 3186.

262.   Wood TL, Wood TK. The HigB/HigA toxin/antitoxin system of *Pseudomonas aeruginosa* influences the virulence factors pyochelin, pyocyanin, and biofilm formation. *MicrobiologyOpen.* 2016;5: 499–511.

263.   Yan J, Bassler BL. Surviving as a Community: Antibiotic Tolerance and Persistence in Bacterial Biofilms*. Cell Host Microbe*. 2019;26: 15–21.

264.   Stewart PS. Antimicrobial Tolerance in Biofilms. *Microbiol Spectr*. 2015;3.

265.   Decano AG, Downing T. An *Escherichia coli* ST131 pangenome atlas reveals population structure and evolution across 4,071 isolates. *Sci Rep.* 2019;9: 17394.

266.   Chung The H, Karkey A, Pham Thanh D, Boinett CJ, Cain AK, Ellington M, et al. A high-resolution genomic analysis of multidrug-resistant hospital outbreaks of *Klebsiella pneumoniae. EMBO Mol Med*. 2015;7: 227–239.

267.   Domman D, Quilici M-L, Dorman MJ, Njamkepo E, Mutreja A, Mather AE, et al. Integrated view of Vibrio cholerae in the Americas. *Science*. 2017. pp. 789–793.

268.   Teng JLL, Yeung M-Y, Yue G, Au-Yeung RKH, Yeung EYH, Fung AMY, et al. *In silico* analysis of 16S rRNA gene sequencing based methods for identification of medically important aerobic Gram-negative bacteria. *J Med Microbiol*. 2011;60: 1281–1286.

269.   Joensen KG, Tetzschner AMM, Iguchi A, Aarestrup FM, Scheutz F. Rapid and Easy *In Silico* Serotyping of *Escherichia coli* Isolates by Use of Whole-Genome Sequencing Data. *J Clin Microbiol*. 2015;53: 2410–2426.

270.   Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol*. 2000;66: 4555–4558.

271.   Clermont O, Christenson JK, Denamur E, Gordon DM. The Clermont *Escherichia coli* phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. *Environ Microbiol Rep*. 2013;5: 58–65.

272.   Page AJ, Keane JA. Rapid multi-locus sequence typing direct from uncorrected long reads using Krocus. *PeerJ.* 2018;6: e5233.

273.   Zhou H, Liu W, Qin T, Liu C, Ren H. Defining and Evaluating a Core Genome Multilocus Sequence Typing Scheme for Whole-Genome Sequence-Based Typing of *Klebsiella pneumoniae. Front Microbiol*. 2017;8: 371.

274.   Kingry LC, Rowe LA, Respicio-Kingry LB, Beard CB, Schriefer ME, Petersen JM. Whole genome multilocus sequence typing as an epidemiologic tool for *Yersinia pestis. Diagn Microbiol Infect Dis*. 2016;84: 275–280.

275.   De Been M, Pinholt M, Top J, Bletz S. Core genome multilocus sequence typing scheme for high-resolution typing of *Enterococcus faecium*. *J Clin Microbiol*. 2015;53(12):3788-3797

276.   Corander J, Waldmann P, Marttinen P, Sillanpaa MJ. BAPS 2: enhanced possibilities for the analysis of genetic population structure. *Bioinformatics*. 2004;20(15):2363-2369.

277.   Lees JA, Harris SR, Tonkin-Hill G, Gladstone RA, Lo SW, Weiser JN, et al. Fast and flexible bacterial genomic epidemiology with PopPUNK. *Genome Res.* 2019;29(2):304-316.

278.   Katz L, Griswold T, Morrison S, Caravas J, Zhang S, Bakker H, et al. Mashtree: a rapid comparison of whole genome sequence files. *Journal of Open Source Software*. 2019;4: 1762.

279.   Ondov BD, Treangen TJ, Melsted P, Mallonee AB, Bergman NH, Koren S, et al. Mash: fast genome and metagenome distance estimation using MinHash. *Genome Biol*. 2016;17: 132.

280.   Kapli P, Yang Z, Telford MJ. Phylogenetic tree building in the genomic age. *Nat Rev Genet*. 2020;21**:** 428–444

281.   Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol.* 2015;32: 268–274.

282.   Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics*. 2014;30: 1312–1313.

283.   Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA, et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. *Microb Genom.* 2017;3: e000131.

284.   Buchfink B, Xie C, Huson DH. Fast and sensitive protein alignment using DIAMOND. *Nat Methods*. 2015;12: 59–60.

285.   Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol.* 1990;215: 403–410.

286.   Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother*. 2012;67: 2640–2644.

287.   Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, et al. *In silico* detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother*. 2014;58: 3895–3903.

288.   Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, et al. ARG-ANNOT (Antibiotic Resistance Gene-ANNOTation), a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. *Antimicrob Agents Chemother*. 2014;58(1):212-220.

289.   Joensen KG, Scheutz F, Lund O, Hasman H, Kaas RS, Nielsen EM, et al. Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic *Escherichia coli*. *J Clin Microbiol*. 2014;52: 1501–1510.

290.	Inouye M, Dashnow H, Raven L-A, Schultz MB, Pope BJ, Tomita T, et al. SRST2: Rapid genomic surveillance for public health and hospital microbiology labs. *Genome Med*. 2014;6: 90.

291.	Durbin R, Eddy SR, Krogh A, Mitchison G. Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids. *Compuational Biology.* Cambridge University Press; 1998;4.

292.	Hyatt D, Chen G-L, Locascio PF, Land ML, Larimer FW, Hauser LJ. Prodigal: prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics.* 2010;11: 119.

293.	Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics*. 2014;30: 2068–2069.

294.	Tanizawa Y, Fujisawa T, Nakamura Y. DFAST: a flexible prokaryotic genome annotation pipeline for faster genome publication. *Bioinformatics.* 2018;34: 1037–1039.

295.	Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST: architecture and applications. *BMC Bioinformatics*. *BMC Bioinformatics* 10, 421 (2009).

296.	Eddy SR. Accelerated Profile HMM Searches. *PLoS Comput Biol*. 2011;7: e1002195.

297.	Haft DH, Selengut JD, White O. The TIGRFAMs database of protein families. *Nucleic Acids Res.* 2003;31: 371–373.

298.	Sonnhammer EL, Eddy SR, Durbin R. Pfam: a comprehensive database of protein domain families based on seed alignments. *Proteins*. 1997;28: 405–420.

299.	Fitch WM. Homology a personal view on some of the problems. *Trends Genet*. 2000;16: 227–231.

300.	Tatusov RL, Galperin MY, Natale DA, Koonin EV. The COG database: a tool for genome-scale analysis of protein functions and evolution. *Nucleic Acids Res*. 2000;28: 33–36.

301.	Li L, Stoeckert CJ Jr, Roos DS. OrthoMCL: identification of ortholog groups for eukaryotic genomes. *Genome Res*. 2003;13: 2178–2189.

302.	Fouts DE, Brinkac L, Beck E, Inman J, Sutton G. PanOCT: automated clustering of orthologs using conserved gene neighborhood for pan-genomic analysis of bacterial strains and closely related species. Nucleic Acids Res. 2012;40: e172.

303.	Altenhoff AM, Glover NM, Dessimoz C. Inferring Orthology and Paralogy. *Evolutionary Genomics: Statistical and Computational Methods*. Springer New York; 2019; 149–175.

304.	Kristensen DM, Kannan L, Coleman MK, Wolf YI, Sorokin A, Koonin EV, et al. A low-polynomial algorithm for assembling clusters of orthologous groups from intergenomic symmetric best matches. *Bioinformatics*. 2010;26: 1481–1487.

305.	Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics*. 2015;31: 3691–3693.

306.	Tonkin-Hill G, MacAlasdair N, Ruis C, Weimann A. Producing Polished Prokaryotic Pangenomes with the Panaroo Pipeline. *bioRxiv*. 2020; 2020.01.28.92298.

doi: https://doi.org/10.1101/2020.01.28.92298

307.   Altenhoff AM, Dessimoz C. Phylogenetic and functional assessment of orthologs inference projects and methods. *PLoS Comput Biol.* 2009;5: e1000262.

308.   Zekic T, Holley G, Stoye J. Pan-Genome Storage and Analysis Techniques. *Comparative Genomics: Methods and Protocols*. Springer New York; 2018; 29–53.

309.   Ding W, Baumdicker F, Neher RA. panX: pan-genome analysis and exploration. *Nucleic Acids Res*. 2018;46: e5.

310.   Lassalle F, Veber P, Jauneikaite E, Didelot X. Automated reconstruction of all gene histories in large bacterial pangenome datasets and search for co-evolved gene modules with Pantagruel. *bioRxiv.* 2019; 586495. doi:10.1101/586495

311.   Horesh G, Harms A, Fino C, Parts L, Gerdes K, Heinz E, et al. SLING: a tool to search for linked genes in bacterial datasets. *Nucleic Acids Res*. 2018;46(21):e128.

312.   Rocha EPC. The organization of the bacterial genome. *Annu Rev Genet.* 2008;42: 211–233.

313.   Itoh T, Takemoto K, Mori H, Gojobori T. Evolutionary instability of operon structures disclosed by sequence comparisons of complete microbial genomes. *Mol Biol Evol.* 1999;16: 332–346.

314.   Price MN, Arkin AP, Alm EJ. The life-cycle of operons. *PLoS Genet*. 2006;2: e96.

315.   Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. An updated evolutionary classification of CRISPR-Cas systems*. Nat Rev Microbiol.* 2015;13: 722–736.

316.   Pandey DP, Gerdes K. Toxin–antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. *Nucleic Acids Res.* 2005;33: 966–976.

317.   Leplae R, Geeraerts D, Hallez R, Guglielmini J, Drèze P, Van Melderen L. Diversity of bacterial type II toxin-antitoxin systems: a comprehensive search and functional analysis of novel families*. Nucleic Acids Res*. 2011;39: 5513–5525.

318.   Xie Y, Wei Y, Shen Y, Li X, Zhou H, Tai C, et al. TADB 2.0: an updated database of bacterial type II toxin-antitoxin loci. *Nucleic Acids Res*. 2018;46(D1):D749-D753.

319.   Shao Y, Harrison EM, Bi D, Tai C, He X, Ou H-Y, et al. TADB: a web-based resource for Type 2 toxin-antitoxin loci in bacteria and archaea. *Nucleic Acids Res*. 2011;39: D606–D611.

320.   Akarsu H, Bordes P, Mansour M, Bigot D-J, Genevaux P, Falquet L. TASmania: A bacterial Toxin-Antitoxin Systems database. *PLoS Comput Biol*. 2019;15: e1006946.

321.   Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture and applications. *BMC Bioinformatics.* 2009;10: 421.

322.   Sevin EW, Barloy-Hubler F. RASTA-Bacteria: a web-based tool for identifying toxin-antitoxin loci in prokaryotes. *Genome Biol.* 2007;8: R155.

323.   Abby SS, Cury J, Guglielmini J, Néron B, Touchon M, Rocha EPC. Identification of protein secretion systems in bacterial genomes. *Sci Rep*. 2016;6: 23080.

324.   Martínez-García PM, Ramos C, Rodríguez-Palenzuela P. T346Hunter: a novel web-based tool for the prediction of type III, type IV and type VI secretion systems in bacterial genomes. *PLoS One*. 2015;10: e0119317.

325.   Costa TRD, Felisberto-Rodrigues C, Meir A, Prevost MS, Redzej A, Trokter M, et al. Secretion systems in Gram-negative bacteria: structural and mechanistic insights. *Nat Rev Microbiol.* 2015;13: 343–359.

326.   Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: biology, mechanisms and applications. *Biochimie*. 2015;117: 119–128.

327.   Anes J, McCusker MP, Fanning S, Martins M. The ins and outs of RND efflux pumps in *Escherichia coli. Front Microbiol*. 2015;6: 587.

328.   Zhang Q, Ye Y. Not all predicted CRISPR--Cas systems are equal: isolated cas genes and classes of CRISPR like elements*. BMC Bioinformatics*. 2017;18: 92.

329.   Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. *Nature.* 2011;477: 462–465.

330.   Reuter S, Connor TR, Barquist L, Walker D, Feltwell T, Harris SR, et al. Parallel independent evolution of pathogenicity within the genus *Yersinia*. *Proc Natl Acad Sci U S A*. 2014;111: 6768–6773.

331.   Cock PJA, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, et al. Biopython: freely available Python tools for computational molecular biology and bioinformatics. *Bioinformatics*. 2009;25: 1422–1423.

332.   Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. *Microb Genom*. 2016;2: e000056.

333.   Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. *Nucleic Acids Res*. 2016;44: W242–5.

334.   Wen Z, Wang P, Sun C, Guo Y, Wang X. Interaction of Type IV Toxin/Antitoxin Systems in Cryptic Prophages of *Escherichia coli* K-12. *Toxins*. 2017;9(3):77.

335.   Wei Y-Q, Bi D-X, Wei D-Q, Ou H-Y. Prediction of Type II Toxin-Antitoxin Loci in Klebsiella pneumoniae Genome Sequences*. Interdiscip Sci.* 2016;8: 143–149.

336.   Brown JM, Shaw KJ. A novel family of *Escherichia coli* toxin-antitoxin gene pairs. *J Bacteriol.* 2003;185: 6600–6608.

337.   Wei Y, Zhan L, Gao Z, Privé GG, Dong Y. Crystal structure of GnsA from *Escherichia coli. Biochem Biophys Res Commun*. 2015;462: 1–7.

338.   Zhang Y, Inouye M. RatA (YfjG), an *Escherichia coli* toxin, inhibits 70S ribosome association to block translation initiation. *Mol Microbiol*. 2011;79: 1418–1429.

339.   Yamaguchi Y, Inouye M. Regulation of growth and death in *Escherichia coli* by toxin–antitoxin systems*. Nat Rev Microbiol.* 2011;9: 779–790.

340.   Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. *Biochem Biophys Res Commun*. 2014;453: 254–267.

341.	Blair JMA, Piddock LJV. Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update. *Curr Opin Microbiol*. 2009;12: 512–519.

342.	The UniProt Consortium. UniProt: the universal protein knowledgebase. *Nucleic Acids Res*. 2017;45: D158–D169.

343.	Godoy P, Molina-Henares AJ, de la Torre J, Duque E, Ramos JL. Characterization of the RND family of multidrug efflux pumps: *in silico* to *in vivo* confirmation of four functionally distinct subgroups. *Microb Biotechnol*. 2010;3: 691–700.

344.	Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. *Bioinformatics*. 2006;22: 1658–1659.

345.	Horesh G, Fino C, Harms A, Dorman MJ, Parts L, Gerdes K, et al. Type II and type IV toxin–antitoxin systems show different evolutionary patterns in the global *Klebsiella pneumoniae* population. *Nucleic Acids Res. 2020;48(8):4357-4370.*

346.	Harms A, Brodersen DE, Mitarai N, Gerdes K. Toxins, Targets, and Triggers: An Overview of Toxin-Antitoxin Biology. *Mol Cell.* 2018;70: 768–784.

347.	Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial Persistence as a Phenotypic Switch. *Science*. 2004; 305(5690):1622-1625.

348.	Moyed HS, Bertrand KP. *hipA*, a newly recognized gene of *Escherichia coli* K-12 that affects frequency of persistence after inhibition of murein synthesis. *J Bacteriol.* 1983;155: 768–775.

349.	Norton JP, Mulvey MA. Toxin-antitoxin systems are important for niche-specific colonization and stress resistance of uropathogenic *Escherichia coli. PLoS Pathog*. 2012;8: e1002954.

350.	Fiedoruk K, Daniluk T, Swiecicka I, Sciepuk M, Leszczynska K. Type II toxin–antitoxin systems are unevenly distributed among *Escherichia coli* phylogroups. *Microbiology*. 2015;161: 158–167.

351.	Fernández-García L, Blasco L, Lopez M, Bou G, García-Contreras R, Wood T, et al. Toxin-Antitoxin Systems in Clinical Pathogens. *Toxins*. 2016;8(7):227.

352.	Lee K-Y, Lee B-J. Structure, Biology, and Therapeutic Application of Toxin–Antitoxin Systems in Pathogenic Bacteria. *Toxins*. 2016;8: 305.

353.	Coray DS, Wheeler NE, Heinemann JA, Gardner PP. Why so narrow: distribution of anti-sense regulated, type I toxin-antitoxin systems compared to type II and type III systems. *RNA Biol*. 2017;14(3):275-280.

354.	Wen Y, Behiels E, Devreese B. Toxin-Antitoxin systems: their role in persistence, biofilm formation, and pathogenicity. *Pathog Dis*. 2014;70: 240–249.

355.	Lobato-Márquez D, Moreno-Córdoba I, Figueroa V, Díaz-Orejas R, García-del Portillo F. Distinct type I and type II toxin-antitoxin modules control *Salmonella* lifestyle inside eukaryotic cells. *Sci Rep*. 2015;5: 9374.

356.	Zerbino DR, Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. *Genome Res.* 2008;18: 821–829.

357.	Page AJ, De Silva N, Hunt M, Quail MA, Parkhill J, Harris SR, et al. Robust high-throughput prokaryote de novo assembly and improvement pipeline for Illumina data.

Microb Genom. 2016;2: e000083.

358.   Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res*. 2004;32: 1792–1797.

359.   Dixon P. VEGAN, a package of R functions for community ecology. *Journal of Vegetation Science.* 2003 Dec;14(6):927-930

360.   Wickham H. ggplot2: Elegant Graphics for Data Analysis. *Use R!* Springer; 2016.

361.   Jones P, Binns D, Chang H-Y, Fraser M, Li W, McAnulla C, et al. InterProScan 5: genome-scale protein function classification. *Bioinformatics*. 2014;30: 1236–1240.

362.   Gotfredsen M, Gerdes K. The *Escherichia coli* relBE genes belong to a new toxin-antitoxin gene family. *Mol Microbiol*. 1998;29(4):1065-1076.

363.   Guzman LM, Belin D, Carson MJ, Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. *J Bacteriol.* 1995;177: 4121–4130.

364.   Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol.* 2013;30: 772–780.

365.   Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2—a multiple sequence alignment editor and analysis workbench. *Bioinformatics.* 2009;25: 1189–1191.

366.   Jurėnas D, Garcia-Pino A, Van Melderen L. Novel toxins from type II toxin-antitoxin systems with acetyltransferase activity. *Plasmid*. 2017;93: 30–35.

367.   Qian H, Yao Q, Tai C, Deng Z, Gan J, Ou H-Y. Identification and characterization of acetyltransferase-type toxin-antitoxin locus in *Klebsiella pneumoniae. Mol Microbiol.* 2018;108: 336–349.

368.   Moyed HS, Broderick SH. Molecular cloning and expression of *hipA*, a gene of *Escherichia coli* K-12 that affects frequency of persistence after inhibition of murein synthesis. *J Bacteriol.* 1986;166: 399–403.

369.   Germain E, Castro-Roa D, Zenkin N, Gerdes K. Molecular mechanism of bacterial persistence by HipA. *Mol Cell.* 2013;52: 248–254.

370.   Heller DM, Tavag M, Hochschild A. CbtA toxin of *Escherichia coli* inhibits cell division and cell elongation via direct and independent interactions with FtsZ and MreB. *PLoS Genet.* 2017;13: e1007007.

371.   Qian H, Yu H, Li P, Zhu E, Yao Q, Tai C, et al. Toxin–antitoxin operon kacAT of Klebsiella pneumoniae is regulated by conditional cooperativity via a W-shaped KacA–KacT complex. *Nucleic Acids Res*. 2019;47(14):7690-7702.

372.   Wright PE, Dyson HJ. Intrinsically disordered proteins in cellular signalling and regulation. *Nat Rev Mol Cell Biol*. 2015;16: 18–29.

373.   Villa L, Capone A, Fortini D, Dolejska M, Rodríguez I, Taglietti F, et al. Reversion to susceptibility of a carbapenem-resistant clinical isolate of *Klebsiella pneumoniae* producing KPC-3. *J Antimicrob Chemother*. 2013;68: 2482–2486.

374.   Harmer CJ, Hall RM. pRMH760, a precursor of A/C$_2$ plasmids carrying *bla*CMY and

*bla*NDM genes. *Microb Drug Resist*. 2014;20: 416–423.

375.   Ho P-L, Lo W-U, Chan J, Cheung Y-Y, Chow K-H, Yam W-C, et al. pIMP-PH114 carrying bla IMP-4 in a Klebsiella pneumoniae strain is closely related to other multidrug-resistant IncA/C2 plasmids. Curr Microbiol. 2014;68: 227–232.

376.   Carattoli A, Villa L, Poirel L, Bonnin RA, Nordmann P. Evolution of IncA/C *bla*CMY-$_2$-carrying plasmids by acquisition of the *bla*NDM-$_1$ carbapenemase gene. *Antimicrob Agents Chemother.* 2012;56: 783–786.

377.   Doublet B, Boyd D, Douard G, Praud K, Cloeckaert A, Mulvey MR. Complete nucleotide sequence of the multidrug resistance IncA/C plasmid *p*R55 from *Klebsiella pneumoniae* isolated in 1969. *J Antimicrob Chemother*. 2012;67: 2354–2360.

378.   Wu K-M, Li L-H, Yan J-J, Tsao N, Liao T-L, Tsai H-C, et al. Genome sequencing and comparative analysis of *Klebsiella pneumoniae* NTUH-K2044, a strain causing liver abscess and meningitis. *J Bacteriol*. 2009;191: 4492–4501.

379.   Chen Y-T, Chang H-Y, Lai Y-C, Pan C-C, Tsai S-F, Peng H-L. Sequencing and analysis of the large virulence plasmid *p*LVPK of *Klebsiella pneumoniae* CG43. *Gene*. 2004;337: 189–198.

380.   Chan WT, Espinosa M, Yeo CC. Keeping the Wolves at Bay: Antitoxins of Prokaryotic Type II Toxin-Antitoxin Systems. *Front Mol Biosci*. 2016;3: 9.

381.   Muthuramalingam M, White JC, Bourne CR. Toxin-Antitoxin Modules Are Pliable Switches Activated by Multiple Protease Pathways. *Toxins*. 2016;8(7):214.

382.   Mitchell AL, Attwood TK, Babbitt PC, Blum M, Bork P, Bridge A, et al. InterPro in 2019: improving coverage, classification and access to protein sequence annotations. *Nucleic Acids Res*. 2019;47: D351–D360.

383.   Saavedra De Bast M, Mine N, Van Melderen L. Chromosomal toxin-antitoxin systems may act as antiaddiction modules. *J Bacteriol*. 2008;190: 4603–4609.

384.   Lin C-Y, Awano N, Masuda H, Park J-H, Inouye M. Transcriptional repressor HipB regulates the multiple promoters in *Escherichia coli. J Mol Microbiol Biotechnol*. 2013;23: 440–447.

385.   Kodama Y, Shumway M, Leinonen R, International Nucleotide Sequence Database Collaboration. The Sequence Read Archive: explosive growth of sequencing data. *Nucleic Acids Res*. 2012;40: D54–6.

386.   Swetha RG, Sekar DKK, Devi ED, Ahmed ZZ, Ramaiah S, Anbarasu A, et al. *Streptococcus pneumoniae* Genome Database (SPGDB): A database for strain specific comparative analysis of *Streptococcus pneumoniae* genes and proteins. *Genomics*. 2014. pp. 582–586.

387.   Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol.* 2012;19: 455–477.

388.   Bayliss SC, Thorpe HA, Coyle NM, Sheppard SK, Feil EJ. PIRATE: A fast and scalable pangenomics toolbox for clustering diverged orthologues in bacteria. *Gigascience*. 2019;8(10):giz119.

389.   Bolger A, Giorgi F. Trimmomatic: a flexible read trimming tool for illumina NGS data.

Bioinformatics. 2014;30(15):2114-2120.

390.   Page AJ, Taylor B, Keane JA. Multilocus sequence typing by blast from de novo assemblies against PubMLST. *J Open Source Softw*. 2016;1: 118.

391.   Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. *PLoS One*. 2010;5: e9490.

392.   Menardo F, Loiseau C, Brites D, Coscolla M, Gygli SM, Rutaihwa LK, et al. Treemmer: a tool to reduce large phylogenetic datasets with minimal loss of diversity. *BMC Bioinformatics*. 2018;19: 164.

393.   Waters NR, Abram F, Brennan F, Holmes A, Pritchard L. Easily phylotyping E. coli via the EzClermont web app and command-line tool. *bioRxiv*. 2018; 317610. doi:10.1101/317610

394.   Pedregosa F, Alexandre Gramfort N, Michel V, Thirion B, Grisel O, Blondel M, et al. Scikit-learn: Machine Learning in Python. *J Mach Learn Res*. 2011;12: 2825–2830.

395.   Paradis E, Claude J, Strimmer K. APE: Analyses of Phylogenetics and Evolution in R language. *Bioinformatics*. 2004;20: 289–290.

396. Yu G, Smith DK, Zhu H, Guan Y, Lam TT. ggtree : an R package for visualization and annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol Evol*. 2017;8: 28–36.

397.   Kallonen T, Brodrick HJ, Harris SR, Corander J, Brown NM, Martin V, et al. Systematic longitudinal survey of invasive *Escherichia coli* in England demonstrates a stable population structure only transiently disturbed by the emergence of ST131. *Genome Res*. 2017;27(8):1437-1449.

398.   Chen SL, Wu M, Henderson JP, Hooton TM, Hibbing ME, Hultgren SJ, et al. Genomic diversity and fitness of *E. coli* strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. *Sci Transl Med*. 2013;5: 184ra60.

399.   Baker KS, Burnett E, McGregor H, Deheer-Graham A, Boinett C, Langridge GC, et al. The Murray collection of pre-antibiotic era Enterobacteriacae: a unique research resource. *Genome Med*. 2015;7: 97.

400.   Alikhan N-F, Zhou Z, Sergeant MJ, Achtman M. A genomic overview of the population structure of *Salmonella*. *PLoS Genet*. 2018;14: e1007261.

401.   Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. *Genome Biol*. 2014;15: R46.

402.   Kim M, Oh H-S, Park S-C, Chun J. Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes. *Int J Syst Evol Microbiol*. 2014;64: 346–351.

403.   Day MJ, Doumith M, Abernethy J, Hope R, Reynolds R, Wain J, et al. Population structure of *Escherichia coli* causing bacteraemia in the UK and Ireland between 2001 and 2010. *J Antimicrob Chemother*. 2016;71: 2139–2142.

404.   Bortolaia V, Larsen J, Damborg P, Guardabassi L. Potential pathogenicity and host range of extended-spectrum beta-lactamase-producing *Escherichia coli* isolates from healthy poultry. *Appl Environ Microbiol*. 2011;77: 5830–5833.

405.	Edgar R, Bibi E. MdfA, an *Escherichia coli* multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. *J Bacteriol*. 1997;179: 2274–2280.

406.	Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18: 268–281.

407.	Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, et al. Origins of the *E. coli* strain causing an outbreak of hemolytic-uremic syndrome in Germany. *N Engl J Med*. 2011;365: 709–717.

408.	Gladstone RA, Lo SW, Lees JA, Croucher NJ, van Tonder AJ, Corander J, et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. *EBioMedicine*. 2019;43: 338–346.

409.	Bidet P, Bonacorsi S, Clermont O, De Montille C, Brahimi N, Bingen E. Multiple insertional events, restricted by the genetic background, have led to acquisition of pathogenicity island IIJ96-like domains among *Escherichia coli* strains of different clinical origins. *Infect Immun*. 2005;73: 4081–4087.

410.	Escobar-Páramo P, Clermont O, Blanc-Potard A-B, Bui H, Le Bouguénec C, Denamur E. A specific genetic background is required for acquisition and expression of virulence factors in *Escherichia coli. Mol Biol Evol*. 2004;21: 1085–1094.

411.	Gordon DM, Cowling A. The distribution and genetic structure of *Escherichia coli* in Australian vertebrates: host and geographic effects. *Microbiology*. 2003;149: 3575–3586.

412.	Farris JS. Methods for Computing Wagner Trees. *Syst Biol*. 1970;19: 83–92.

413.	Huerta-Cepas J, Forslund K, Coelho LP, Szklarczyk D, Jensen LJ, von Mering C, et al. Fast Genome-Wide Functional Annotation through Orthology Assignment by eggNOG-Mapper. *Mol Biol Evol*. 2017;34: 2115–2122.

414.	Galperin MY, Makarova KS, Wolf YI, Koonin EV. Expanded microbial genome coverage and improved protein family annotation in the COG database. *Nucleic Acids Res.* 2015;43: D261–9.

415.	Dallman T, Cross L, Bishop C, Perry N, Olesen B, Grant KA, et al. Whole genome sequencing of an unusual serotype of Shiga toxin-producing *Escherichia coli. Emerg Infect Dis*. 2013;19: 1302–1304.

416.	Ewers C, Bethe A, Stamm I, Grobbel M, Kopp PA, Guerra B, et al. CTX-M-15-D-ST648 *Escherichia coli* from companion animals and horses: another pandemic clone combining multiresistance and extraintestinal virulence? *J Antimicrob Chemother*. 2014;69: 1224–1230.

417.	Paulshus E, Thorell K, Guzman-Otazo J, Joffre E, Colque P, Kühn I, et al. Repeated Isolation of Extended-Spectrum-β-Lactamase-Positive *Escherichia coli* Sequence Types 648 and 131 from Community Wastewater Indicates that Sewage Systems Are Important Sources of Emerging Clones of Antibiotic-Resistant Bacteria. *Antimicrob Agents Chemother.* 2019;63(9):e00823-19

418.	Oteo J, Diestra K, Juan C, Bautista V, Novais A, Pérez-Vázquez M, et al. Extended-spectrum beta-lactamase-producing *Escherichia coli* in Spain belong to a large variety

of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. *Int J Antimicrob Agents*. 2009;34: 173–176.

419.   Matamoros S, van Hattem JM, Arcilla MS, Willemse N, Melles DC, Penders J, et al. Global phylogenetic analysis of *Escherichia coli* and plasmids carrying the *mcr-1* gene indicates bacterial diversity but plasmid restriction. *Sci Rep*. 2017;7: 15364.

420.   Yang F, Yang J, Zhang X, Chen L, Jiang Y, Yan Y, et al. Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery. *Nucleic Acids Res.* 2005;33: 6445–6458.

421.   Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a New Metallo-β-Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in *Klebsiella pneumoniae* Sequence Type 14 from India. *Antimicrob Agents Chemother.* 2009;53(12):5046-5054*.*

422.   Stoesser N, Sheppard AE, Pankhurst L, De Maio N, Moore CE, Sebra R, et al. Evolutionary History of the Global Emergence of the *Escherichia coli* Epidemic Clone ST131. *MBio*. 2016;7: e02162.

423.   Bradley P, den Bakker HC, Rocha EPC, McVean G, Iqbal Z. Ultrafast search of all deposited bacterial and viral genomic data. *Nat Biotechnol*. 2019;37: 152–159.

424.   Chang W, Cheng J, Allaire J, Xie Y, McPherson J et al. Shiny: web application framework for R. *RStudio, Inc*. 2017;1.

425.   Almeida A, Mitchell AL, Boland M, Forster SC, Gloor GB, Tarkowska A, et al. A new genomic blueprint of the human gut microbiota. *Nature*. 2019;568: 499–504.